Shl Telemedicine Ltd. · SIX:SHLTN
Shl Telemedicine — H1 2023 Earnings Presentation
15 slides from Shl Telemedicine's earnings presentation, September 2023
Slide 1: SHL Telemedicine HY Results 2023 Presentation
SHL Telemedicine HY Results 2023 Presentation 1
Slide 2: Forward looking statements
Forward looking statements This presentation was prepared for the purpose of providing and presenting information in a summary only and cannot replace a review of the reports of SHL Telemedicine (hereinafter: "the Company"). Many of the statements included in this presentation, as well as oral state
Slide 3: SHL Telemedicine at a glance
SHL Telemedicine at a glance Telemedicine centers in Israel & Listed on Germany Significant strategic partners in the US market Nasdaq: SHLT SWX: SHLTN 1HY 2023 revenues interactions and data 3M $29.0M readings per year 30+ years of experience SHL is a leading provider and 24/7 telehealth monitoring
Slide 4: HY 2023 Overview Financial Data
HY 2023 Overview Financial Data(*) REVENUES Adjusted EBITDA(*) Operational CASH Flow $29.0M $ 0.4M $ (3.3)M CASH On Hand CASH On HAND R&D Gross Expenses ~$28.6M $29.4M $3.6M Currently 30 June 2023 (*) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA
Slide 5: Germany: A promising new growth engine
Germany: A promising new growth engine SHL is the market leader in Germany and operates 1HY2022 2HY2022 1HY2023 in a B2B model - managing and stabilizing chronic patients and saving costs for health insurers REVENUES(*) REVENUES(*) REVENUES The company has agreements with leading health $7.0M $6.7M
Slide 6: Germany - Virtual Visit service
Germany - Virtual Visit service: Penetrating a market of about 800 million annual physical doctor visits BARMER - a new 7-year contract Commercial service started April 2023 Pay Per Use model Successfully fending major players like Teladoc, and In Germany - an average of 10 physical a path for growt
Slide 7: USA
USA Prioritization of direct-to-consumer sales in 2HY 2023- considering hospitals’ financial strains; Awaiting Mayo Clinic study results REVENUES $0.6M DTC plan: more Leveraging the Tier1 Strategic customers relationships strengthen cash-efficient and network of our reputation in support of the Smar
Slide 8: USA: Promising Initial Results in Mayo Clinic and Imperial College Trials
USA Promising Initial Results(*) in Mayo Clinic and Imperial College Trials Mayo Clinic – HELP MI Imperial College London - TELE-ACS Reduction Reduction 43% in “any ED Hospitalization” 55% in hospital readmission Reduction Reduction 33% in “any ED visit” 27.5% in ED attendance ZERO CV ED visit or Ho
Slide 9: Israel
Israel High contribution to the company's profitability and cash flow The leader in B2C Telemedicine Services 1HY2022 2HY2022 1HY2023 Sale of cardiac monitoring services to consumers: personal 12 Lead ECG devices for REVENUES(*) REVENUES(*) REVENUES transmission of remote medical data, 24/7 telemedi
Slide 10: Financials – P&L
Financials – P&L Revenue In USD million 30,000 1HY 2023 1HY 2022cc* 29,500 (except per share amounts) 29,000 28,500 28,000 Revenues for the period 29.0 28.8 27,500 27,000 Revenues by territories HY-2022 HY-2023 Germany 6.8 7.0 4,000 R&D Gross exp 3,500 Israel 21.6 21.0 3,000 2,500 Rest of the World
Slide 11: Financials – Balance sheet & Cash flow
Financials – Balance sheet & Cash flow In USD million 1HY 2023 1HY 2022 Cash and cash equivalents 10.4 16.4 Short term investments 19.0 8.7 Total cash and short-term investments 29.4 25.1 Short term bank debt 2.1 2.2 Total Assets Long term bank debt 11.3 14.2 130 Total bank debt 13.4 16.4 120 110 Ca
Slide 12: 2HY 2023 – Expected Events
2HY 2023 – Expected Events Constant increase in Agreements with additional health the use of Virtual Visits funds for Virtual Visit services Increased growth Publication of results Continued study for use of implementation of With our B2B model – Tier 1 customers Start of B2C sales 12
Slide 13: Thank You
Thank You SHL Telemedicine 13
Slide 14: Supplement Information
Supplement Information Reconciliation of Adjusted EBITDA and Adjusted In the table below, HY 2022 results have been EBIT to net profit as required by the rules of the U.S. presented at HY 2023 exchange rates1. Management Securities Exchange Commission with respect to believes that this presentation
Slide 15: Supplement Information
Supplement Information Reconciliation of Adjusted EBITDA and Adjusted in USD million 1HY2022 EBIT to net profit as required by the rules of the U.S. 1HY2023 1HY2022 (CC1) Securities Exchange Commission with respect to non-GAAP financial measures (HY2022 results are Net profit (loss) (2.1) 0.1 (0.1)